Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children

Haematologica

Volumn 90, Issue 12, 2005, Pages 1701-1703

  Horstmann, Martin A ^a   Hassenpflug, Wolf Achim ^a   Zur Stadt, Udo ^a   Escherich, Gabi ^a   Janka, Gritta ^a   Kabisch, Hartmut ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute lymyhoblastic leukemia; Amsacrine; Etoposide; Minimal residual disease; Pediatrics; Prednisolone; Salvage

Indexed keywords

AMSACRINE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; PREDNISOLONE; THIOTEPA; TOPOTECAN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INFECTIOUS COMPLICATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTARABINE; DEOXYCYTIDINE; DEXAMETHASONE; DRUG EVALUATION; DRUG SYNERGISM; ETOPOSIDE; FEMALE; FILGRASTIM; HUMANS; IDARUBICIN; INFANT; LEUKEMIA, CALLA-POSITIVE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LEUKEMIA, PRE-B-CELL; LEUKEMIA, T-CELL, ACUTE; MALE; METHYLPREDNISOLONE; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; THIOTEPA; TOPOTECAN; TREATMENT OUTCOME; VIDARABINE; VINBLASTINE;

EID: 29144478680     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Uckun FM, Kersey JH, Haake R, Weisdorf D, Nesbit ME, Ramsay NK. Pretransplantation burden of leukemic progenitor cells as a predictor or relapse after bone marrow transplantation for acute lymphoblastic leukemia. N Engl J Med 1993;329:1296-301.
2. Van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003;17:1013-34.
3. Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998;102:647-55.
4. Kolb EA, Steinherz PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 2003;17:1967-72.
5. Knechtli CJ, Goulden NJ, Hancock JP, Grandage V, Harris EL, Graland RJ, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998;92:4072-9.
6. Steuber CP, Krischer J, Holbrook T, Camitta B, Land V, Sexauer C, et al. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 1996;14:1521-5.
7. Freudenreich CH, Kreuzer KN. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc Natl Acad Sci USA 1994;9l:11007-10.
8. Grabowski DR, Holmes KA, Aoyama M, Ye Y, Rybicki LA, Bukowski RM, et al. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide. Mol Pharmacol 1999;56:1340-5.
9. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89, and 92. Leukemia 2000;14:2234-9.
10. Henze G, Fengler R, Hartmann R, Komhuber B, Janka-Schaub G, Niethammer D, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991;78:1166-72.